Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, is indicated for the management of glycemic control in type 2 diabetes mellitus, together with a controlled diet and physical activity. Here, DPP4 is linked to diabetes mellitus.